Full video transcriptClick to expand
Auto-generated transcript of @wrenchboss_nj's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00This is my face day one on Zetbound.
- 0:02Just got this prescribed to me and it cost me a pretty penny.
- 0:06Um, $372 worth insurance.
- 0:09That's...
- 0:10Wow.
- 0:11Zetbound is used to treat sleep apnea and weight loss.
- 0:15It's kind of like Ozempic, but not really the same.
- 0:17It's different ingredients.
- 0:18The difference between Zetbound and Ozempic is Ozempic is used for type two diabetes
- 0:23and cardiovascular disease, where this is used for sleep apnea and weight loss, I guess.
- 0:30Zetbound is more proven to lose weight compared to Ozempic.
- 0:33I don't know.
- 0:34My got there prescribed me this and uh, I'm gonna give it a try for one month and see what happens.
- 0:40$372 is a hefty price tag for this prescription.
- 0:45It actually would have been like $1300 if I wouldn't have had insurance, which is whoa, I would have never done that.
- 0:50But if I don't like it, I won't do it.
- 0:51I mean, I'm losing weight on my own right now.
- 0:53I'm not giving you guys an update on that just yet, because I'm waiting for the 20-day mark since I started on Adderall,
- 0:59and losing weight.
- 1:00So that's coming, stay tuned for that.
- 1:02But I will let you guys know what I think about this, and I'm gonna be very, very public about it because I am a social media influencer,
- 1:08and this is the first major medication I've ever taken, so uh, we'll see how it goes.
Zepbound day-one videos: what TikTok gets right and wrong
Quick answer
Tirzepatide (Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and as of June 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity. The creator is starting at the lowest dose with concurrent Adderall use, which warrants provider monitoring given overlapping appetite-suppressing and cardiovascular effects. Weight loss outcomes in trials averaged roughly 15-21% of body weight depending on dose and duration, but individual results vary significantly based on adherence, baseline health, and titration schedule.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Compounded Tirzepatide access requires the right clinical path
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For Zepbound day-one videos: what TikTok gets right and wrong, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Primary STEP 1 trial source for semaglutide weight-management efficacy and adverse-event context.
PubMed
Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance
Used for maintenance, discontinuation, and weight-regain discussions after semaglutide response.
PubMed
Tirzepatide Once Weekly for the Treatment of Obesity
Primary SURMOUNT-1 trial source for tirzepatide weight-loss ranges and tolerability.
PubMed
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction
Used for continuation, stopping, and maintenance questions after initial weight loss.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
Compounded Tirzepatide should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
If the claim matches your goal, use the get-started flow to move from curiosity into a supervised prescription review.
Claim path
Keep researching this tirzepatide video claims cluster
Best for searchers deciding whether tirzepatide claims are stronger, safer, or more relevant than semaglutide claims.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "Zepbound day-one videos: what TikTok gets right and wrong" from wrenchboss_nj. We read the clip as a GLP-1 social video fact-checks claim about Compounded Tirzepatide, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: Tirzepatide (Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and as of June 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.
The reason this review is not generic is the source wording and the canonical claim label "glp1 day 1 on zepbound." In this clip, the useful excerpt is: "This is my face day one on Zetbound." That wording changes the review because it points to Compounded Tirzepatide safety, access, evidence, and fit, not a one-size-fits-all protocol.
The source trail for this page is checked against Once-Weekly Semaglutide in Adults with Overweight or Obesity (2021), Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance (2021), and Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight (2022), plus the creator's own wording. Compounded Tirzepatide still needs an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
Tirzepatide (Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and as of June 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity.
FormBlends verdict
Compounded Tirzepatide safety, access, evidence, and fit
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with the Compounded Tirzepatide guide, safety notes, access rules, and a licensed-provider review.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- Tirzepatide (Zepbound) is an FDA-approved dual GIP/GLP-1 receptor agonist indicated for chronic weight management in adults with obesity or overweight with at least one weight-related condition, and as of June 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity. The creator is starting at the lowest dose with concurrent Adderall use, which warrants provider monitoring given overlapping appetite-suppressing and cardiovascular effects. Weight loss outcomes in trials averaged roughly 15-21% of body weight depending on dose and duration, but individual results vary significantly based on adherence, baseline health, and titration schedule.
- Tirzepatide (Zepbound) received FDA approval for obstructive sleep apnea in June 2024, specifically for adults with obesity, based on the SURMOUNT-OSA trial published in NEJM.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed approximately 20.9% mean body weight reduction with tirzepatide 15mg over 72 weeks, compared to approximately 14.9% for semaglutide 2.4mg in STEP 1 (Wilding et al., 2021, NEJM), but these are not head-to-head trial results.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compounded Tirzepatide decisions still need source quality, legal access, and provider oversight checks.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against the Compounded Tirzepatide guide, cost path, safety notes, and provider review before acting.
Review Compounded TirzepatideWhat You'll Learn
- Tirzepatide (Zepbound) received FDA approval for obstructive sleep apnea in June 2024, specifically for adults with obesity, based on the SURMOUNT-OSA trial published in NEJM.
- SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed approximately 20.9% mean body weight reduction with tirzepatide 15mg over 72 weeks, compared to approximately 14.9% for semaglutide 2.4mg in STEP 1 (Wilding et al., 2021, NEJM), but these are not head-to-head trial results.
- Semaglutide is approved for weight management under the brand name Wegovy, not Ozempic. Conflating the two misleads patients about what drugs are available for which conditions.
- Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist only. This mechanistic difference is why their efficacy and side effect profiles may vary.
- Concurrent use of GLP-1 medications and stimulants such as Adderall should be managed by a provider who is aware of both prescriptions, given potential additive effects on appetite suppression and heart rate.
- Zepbound's list price is approximately $1,059 to $1,349 per month without insurance. Eli Lilly's savings card program can reduce costs for eligible commercially insured patients, but does not apply to Medicare or Medicaid enrollees.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @wrenchboss_nj actually say?
On day one of his Zepbound prescription, @wrenchboss_nj laid out his understanding of the drug for 56,000-plus viewers. He said Zepbound "is used to treat sleep apnea and weight loss," called it "kind of like Ozempic, but not really the same," and argued the key difference is that Ozempic is for "type two diabetes and cardiovascular disease" while Zepbound targets sleep apnea and weight. He also claimed Zepbound "is more proven to lose weight compared to Ozempic." He paid $372 with insurance, noted the list price would have been roughly $1,300, and was transparent that he's currently losing weight on his own and taking Adderall. Credit where it's due: that level of disclosure is genuinely rare on weight-loss TikTok.
Does the science back this up?
Partially, but the framing has real problems. Tirzepatide (Zepbound) and semaglutide (Ozempic/Wegovy) are not just different brands of the same mechanism. That distinction matters clinically, and the weight-loss comparison is more complicated than "more proven."
Tirzepatide is a dual GIP/GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist only. In the SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM), tirzepatide at the highest dose produced mean weight loss of about 20.9% of body weight over 72 weeks in adults with obesity. In the STEP 1 trial (Wilding et al., 2021, NEJM), semaglutide 2.4mg produced about 14.9% mean weight loss. So tirzepatide does show larger average weight loss in trials, though these are different study populations and not head-to-head comparisons. Calling it "more proven" oversimplifies a legitimate but nuanced finding.
On sleep apnea: the FDA approved Zepbound for moderate-to-severe obstructive sleep apnea in adults with obesity in June 2024, based on the SURMOUNT-OSA trial (Malhotra et al., 2024, NEJM). That is a real, recent, and specific approval. He got that right.
What did they get wrong (or right)?
The Ozempic framing is where things slip. Saying Ozempic is used "for type two diabetes and cardiovascular disease" while Zepbound is for "sleep apnea and weight loss" sets up a false either/or. Ozempic is FDA-approved for type 2 diabetes and cardiovascular risk reduction, yes. But semaglutide at 2.4mg (branded Wegovy) is also FDA-approved for chronic weight management. Conflating Ozempic and Wegovy, which happens constantly on social media, misleads people about what's actually available for weight loss.
He also says tirzepatide has "different ingredients" than Ozempic, which is technically true but vague in a way that might imply they're completely unrelated drug classes. They share a GLP-1 mechanism. The difference is tirzepatide adds GIP agonism, which is meaningfully distinct but not a total departure.
What he got right: the sleep apnea indication is accurate. The price transparency is valuable. And his acknowledgment that he's "losing weight on my own right now" suggests he's not treating this as a magic fix, which is the right frame for any GLP-1 therapy.
What should you actually know?
If you're considering Zepbound or any GLP-1 therapy after watching videos like this, a few things are worth understanding before you talk to a provider.
- Tirzepatide (Zepbound/Mounjaro) and semaglutide (Ozempic/Wegovy) are related but mechanistically different drugs. Your eligibility, insurance coverage, and likely response may differ based on your specific health profile.
- The sleep apnea approval for Zepbound is specifically for adults with obesity, not a standalone sleep apnea treatment. Weight loss is the mechanism, not a direct action on airway anatomy.
- The weight-loss comparison between tirzepatide and semaglutide is promising but not settled. No large randomized head-to-head trial comparing them directly for weight loss has been published as of early 2025.
- $372 with insurance and roughly $1,300 without reflects a real access problem for this drug class. Manufacturer savings cards can reduce out-of-pocket costs, but eligibility varies and these programs have income and insurance restrictions.
- Combining GLP-1 medications with stimulants like Adderall is something that requires explicit provider oversight. Both can suppress appetite and affect cardiovascular function. This is not a stack to manage informally.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
wrenchboss_nj · TikTok creator
56.5K views on this video
Day 1 on #zepbound
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about tirzepatide (zepbound) received fda approval for obstructive sleep apnea in?
Tirzepatide (Zepbound) received FDA approval for obstructive sleep apnea in June 2024, specifically for adults with obesity, based on the SURMOUNT-OSA trial published in NEJM.
What does the video say about surmount-1 (jastreboff et al., 2022, nejm) showed approximately 20.9% mean?
SURMOUNT-1 (Jastreboff et al., 2022, NEJM) showed approximately 20.9% mean body weight reduction with tirzepatide 15mg over 72 weeks, compared to approximately 14.9% for semaglutide 2.4mg in STEP 1 (Wilding et al., 2021, NEJM), but these are not head-to-head trial results.
What does the video say about semaglutide?
Semaglutide is approved for weight management under the brand name Wegovy, not Ozempic. Conflating the two misleads patients about what drugs are available for which conditions.
What does the video say about tirzepatide?
Tirzepatide is a dual GIP and GLP-1 receptor agonist. Semaglutide is a GLP-1 receptor agonist only. This mechanistic difference is why their efficacy and side effect profiles may vary.
What does the video say about concurrent use of glp-1 medications?
Concurrent use of GLP-1 medications and stimulants such as Adderall should be managed by a provider who is aware of both prescriptions, given potential additive effects on appetite suppression and heart rate.
What does the video say about zepbound's list price?
Zepbound's list price is approximately $1,059 to $1,349 per month without insurance. Eli Lilly's savings card program can reduce costs for eligible commercially insured patients, but does not apply to Medicare or Medicaid enrollees.
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by wrenchboss_nj, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.